SERVET KÖLGELİER, NAZLIM AKTUĞ DEMİR, ŞUA SÜMER, LÜTFİ SALTUK DEMİR, ABDULLAH ARPACI, ONUR URAL

Transfusion transmitted virüs (ttv) prevalansıinaktif hepatit b taşıyıcılarında hemodiyalizden etkileniyor mu?

Amaç: Bu çalışmada, hemodiyaliz tedavisi uygulanan ve uygulanmayan inaktif hepatit B taşıyıcılarında Transfusion Transmitted Virus (TTV) prevalansının saptanması amaçlandı. Gereç ve Yöntem: Bu çalışma, hemodiyaliz tedavisi uygulanan 50 inaktif hepatit B hastası ve renal fonksiyonları normal olan 40 inaktif hepatit B olgusu üzerinde yapıldı. Hastalardan alınan serum örneklerinden ELİSA kiti ile Anti TTV IGG çalışıldı. Veriler Ki-kare testi ile değerlendirildi. Bulgular: 50 hemodiyaliz hastasının 39’unda (%78) Anti TTV IGG pozitif saptanırken, 40 hemodiyaliz tedavisi uygulanmayan inaktif hepatit B hastasının 8’inde (%20) Anti TTV IGG pozitifliği saptandı. Bu fark istatistiki olarak anlamlı idi (p=0.001). Sonuç: Hemodiyaliz tedavisi uygulanan hastalarda TTV seropozitifliğinin yüksek olması nedeniyle, hepatit virüslerinin bulaşının önlenmesi için bu ünitelerde temizlik, dezenfeksiyon ve enfeksiyon kontrolüne yönelik standart önlemlerin daha dikkatli uygulanması gerektiğini düşünüyoruz.

Objective: Inthisstudy, it was aimed to determine the prevalence of Transfusion Transmitted Virus (TTV) virus in inactivated hepatitis B carriers with and without hemodialysis treatment. Materials and Methods: This study was conducted on 50 inactive hepatitis B patients treated with hemodialysis and 40 inactive hepatitis B patients with normal renal function. Anti-TTV IGG was studied with ELISA kit from serum samples taken from patients. Data were evaluated by Chi-square test. Results: Anti-TTV IGG positivity was detected in 39 (78%) of 50 hemodialysis patients while Anti-TTV IGG positivity was detected in 8 (20%) of 40 inactivated hepatitis B patients without hemodialysis. This difference was statistically significant (p=0.001). Conclusion: We think that standard measures for cleaning, disinfection and infection control should be applied more carefully in these units in order to prevent transmission of hepatitis viruses because of the high TTV seropositivity in hemodialysis patients.

PDF

___

Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virüs (TTV) associated with elevated transaminase levels in post transfusion hepatitis of unknown etiology. Biochem Biophys Res Commun1997;24:92-7.

Özener Çİ, Türe F, Koç M,Avşar E. SAPD Hastalarında TT Virüs (TTV) Enfeksiyonu ve Prevelansı.Turk Neph Dial Transpl 2001;10:93-7.

Tanaka H, Okamoto H, Luengrojanakul P, et al.Infection with an unenveloped DNA virus (TTV) associated with posttransfusion non-A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. J Med Virol 1998;56:234-8.

Kheradpezhouh M, Taremi M, Gachkar L. Presence andsignificance of transfusion-transmitted virus infection in Iranian patients on maintenance hemodialysis. J Microbiol Immunol Infect 2007;40:106-11.

Chan YJ, Hsu YH, Chen MC et al. TT virus infection among hemodialysis patients at a medical center in Taiwan. J Microbiol Immunol Infect 2000;33:14-8.

Yılmaz N, Çiftçi A, Balcı M, et al.Hemodiyaliz Hastalarında Hepatit E, Hepatit G Ve TTV Seroprevalansı. OrtadoguMed J 2017;9:6-11.

Rivanera D, Lozzi MA, Idili C, Lilli D. Prevalence of TT virus infection in Italian dialysis patients. Pathol Biol 2009;57:97-100.

Valtuille R, Frankel F, Gomez F, et al. The role of transfusion-transmitted virus in patients undergoing hemodialysis. J Clin Gastroenterol 2002;34:86-8.

Schroter M, Feucht HH, Zollner B, Schafer P, Laufs R. Prevalence of a novel DNA virus (TTV) among patients on maintenance hemodialysis. Nephron 2001;87:139-42.

Chattopadhyay S, Rao S, Das BC, Singh NP, Kar P. Prevalence of transfusion-transmitted virus infection in patients on maintenance hemodialysis from New Delhi, India. Hemodial Int 2005;9:362-6.

Türkoğlu S. TTV'nin farklı hasta gruplarında araştırılması. Türk Mikrobiol Cem Derg 2001;31:259-61.

Simmonds P, Davidson F, Lycett C, et al.Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet 1998;352:191-5.

Prescott LE, Simmonds P. Global distribution of transfusion-transmitted virus. N Engl J Med 1998;339:776–7.

Ukita M, Okamoto H, Kato N, Miyakawa Y, Mayumi M.Excretion in to bile of a novelunenveloped DNA virus (TTV virus) associated with acute and chronic non-A-G hepatitis. J Infect Dis 1999;179:1245-8.

Prescott LE, Simmonds P. Global distribution of transfusion-transmitted virus. N Engl J Med 1998;339: 776-7.

Desai SM, Muerhoff AS, Leary TP, et al. Prevalence of TT virus infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses. J Infect Dis 1999;179:1242-4.

Tunçbilek S, Coşkun D, Çetinkaya F, Hizel N, Tahtakılıç P. İstanbul'da kan donörlerinde TT virusu (TTV) prevalansının araştırılması. Flora 1999;4:273-7.

Usta M, Dilek K, Ersoy A, et al. Prevalence of transfusion transmitted virus infection and its effect on renal graftsurvival in renal transplant recipients. Scand J Urol Nephrol 2002;36:473-7.

Savaş MC, Güney Ç, Kadayıfçı A, et al. High prevalence of transfusion-transmitted virüs infection in patients with chronic liver diseases in an endemic area of hepatitis B and C virüs. Med Prin Pract Med 2003;12:176-9.

Yenice N, Gökden Y, Erdem L, Türkmen S, Arican N. Transfusional transmitted virüs seroprevalence in asymptomatic HBsAg (+) hepatitis B carriers. Scand J Gastroenterol 2004;39:174-7.

Irshad M, Mandal K, Singh S, Agarwal SK. Torqueteno virus infection in hemodialysis patients in North India. Int Urol Nephrol 2010;42:1077-83.